Literature DB >> 9531434

Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease.

D Nilsson1, L E Hansson, K Johansson, C Nyström, L Paalzow, S M Aquilonius.   

Abstract

OBJECTIVE: To evaluate the effects of continuous duodenal infusion of levodopa over time on the disabling fluctuations in motor performance in advanced parkinsonian patients. It has earlier been demonstrated that these fluctuations can be reduced by keeping the plasma concentration of levodopa constant.
MATERIAL AND METHODS: In view of the low water solubility of levodopa a stable dispersion of the drug was developed and used for continuous intraduodenal infusion in patients with advanced Parkinson's disease. Nine patients were evaluated with respect to an optimal oral treatment, during nasoduodenal infusion by a portable pump and then followed for 6 months to 2 1/2 years when treated via transabdominal infusion. Upon each test occasion, over 2 non-consecutive days, objective movement analysis by means of an opto-electronic system was applied every 15-20 min and video recordings performed twice every h. On several test occasions plasma levodopa concentrations were analysed every 15 min.
RESULTS: The patients showed improvement and decreased variance of their motor function. In the 2 patients followed over a period of 2 1/2 years levodopa plasma concentration showed reduced fluctuations on infusion and the levodopa consumption as well as mean levodopa plasma concentration decreased.
CONCLUSION: Continuous duodenal infusion of levodopa is an alternative treatment strategy for patients with advanced Parkinson's disease when conventional therapy has failed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531434     DOI: 10.1111/j.1600-0404.1998.tb00633.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  17 in total

1.  Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.

Authors:  Maurizio Zibetti; Aristide Merola; Valeria Ricchi; Alice Marchisio; Carlo Alberto Artusi; Laura Rizzi; Elisa Montanaro; Dario Reggio; Claudio De Angelis; Mario Rizzone; Leonardo Lopiano
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

Review 2.  Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.

Authors:  P Jenner; A C McCreary; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 3.  Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.

Authors:  Yasaman Kianirad; Tanya Simuni
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

4.  Production of novel NaN3-resistant creatine amidinohydrolase in recombinant Escherichia coli.

Authors:  Song Liu; Jun Dai; Zhen Kang; Jianghua Li; Jian Chen; Guocheng Du
Journal:  Bioengineered       Date:  2015       Impact factor: 3.269

5.  Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer.

Authors:  Sam Habet
Journal:  Int J Neuropsychopharmacol       Date:  2022-08-04       Impact factor: 5.678

Review 6.  Initiation of Parkinson's disease treatment.

Authors:  Heinz Reichmann
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

7.  Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.

Authors:  María T Cáceres-Redondo; Fátima Carrillo; María J Lama; Ismael Huertas-Fernández; Laura Vargas-González; Manuel Carballo; Pablo Mir
Journal:  J Neurol       Date:  2014-01-30       Impact factor: 4.849

Review 8.  Medical management of levodopa-associated motor complications in patients with Parkinson's disease.

Authors:  Joseph Jankovic; Mark Stacy
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Authors:  Cheryl H Waters; Paul Nausieda; Lyudmila Dzyak; Joerg Spiegel; Monika Rudzinska; Dee E Silver; Elena S Tsurkalenko; Sherron Kell; Ann Hsu; Sarita Khanna; Suneel Gupta
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

10.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.